JT Stratford LLC Invests $257,000 in Insulet Co. (NASDAQ:PODD)

JT Stratford LLC acquired a new position in shares of Insulet Co. (NASDAQ:PODD - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 986 shares of the medical instruments supplier's stock, valued at approximately $257,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Sheets Smith Wealth Management increased its position in shares of Insulet by 37.2% during the fourth quarter. Sheets Smith Wealth Management now owns 1,371 shares of the medical instruments supplier's stock valued at $358,000 after acquiring an additional 372 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of Insulet by 1.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier's stock worth $1,146,000 after acquiring an additional 43 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Insulet by 295.9% during the 4th quarter. SG Americas Securities LLC now owns 23,892 shares of the medical instruments supplier's stock worth $6,237,000 after purchasing an additional 17,857 shares during the period. Whalen Wealth Management Inc. acquired a new stake in Insulet in the 4th quarter valued at approximately $257,000. Finally, Donoghue Forlines LLC acquired a new stake in Insulet in the 4th quarter valued at approximately $2,039,000.

Insider Buying and Selling at Insulet

In related news, SVP John W. Kapples sold 5,278 shares of the company's stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the transaction, the senior vice president now directly owns 23,180 shares of the company's stock, valued at $7,382,134.60. This represents a 18.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Wayne A.I. Frederick sold 1,825 shares of the firm's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the sale, the director now directly owns 3,231 shares in the company, valued at approximately $888,525. The trade was a 36.10% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by insiders.

Insulet Stock Down 1.1%

Shares of Insulet stock opened at $321.00 on Friday. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a 52-week low of $170.67 and a 52-week high of $329.33. The company has a market capitalization of $22.59 billion, a P/E ratio of 55.44, a P/E/G ratio of 3.62 and a beta of 1.26. The company has a 50 day moving average of $269.92 and a 200 day moving average of $268.95.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, beating analysts' consensus estimates of $0.81 by $0.21. The business had revenue of $569.00 million for the quarter, compared to analyst estimates of $543.20 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company's revenue was up 28.8% on a year-over-year basis. During the same period last year, the business earned $0.73 EPS. As a group, research analysts forecast that Insulet Co. will post 3.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PODD has been the topic of a number of research reports. Sanford C. Bernstein restated an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Piper Sandler boosted their price objective on Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a report on Friday, February 21st. Wolfe Research upgraded Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 target price for the company in a report on Tuesday, May 13th. Barclays lifted their target price on Insulet from $234.00 to $266.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 30th. Finally, Canaccord Genuity Group boosted their price target on shares of Insulet from $304.00 to $324.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Four research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company's stock. According to data from MarketBeat, Insulet currently has an average rating of "Moderate Buy" and an average target price of $308.00.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.